235 related articles for article (PubMed ID: 22487610)
21. Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study.
De Jong MA; Eisenga MF; van Ballegooijen AJ; Beulens JWJ; Vervloet MG; Navis G; Gansevoort RT; Bakker SJL; De Borst MH
Nephrol Dial Transplant; 2021 Jan; 36(1):121-128. PubMed ID: 32124925
[TBL] [Abstract][Full Text] [Related]
22. What would we like to know, and what do we not know about fibroblast growth factor 23?
Cozzolino M; Galassi A; Apetrii M; Covic A
J Nephrol; 2011; 24(6):696-706. PubMed ID: 21786227
[TBL] [Abstract][Full Text] [Related]
23. Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the "trade-off" hypothesis.
Gutiérrez OM
Clin J Am Soc Nephrol; 2010 Sep; 5(9):1710-6. PubMed ID: 20507957
[TBL] [Abstract][Full Text] [Related]
24. [Potential application of fibroblast growth factor 23-klotho axis in chronic kidney disease].
Lacroix JS; Urena-Torres P
Nephrol Ther; 2020 Mar; 16(2):83-92. PubMed ID: 31843356
[TBL] [Abstract][Full Text] [Related]
25. FGF-23 and Osteoprotegerin but not Fetuin-A are associated with death and enhance risk prediction in non-dialysis chronic kidney disease stages 3-5.
Alderson HV; Ritchie JP; Middleton R; Larsson A; Larsson TE; Kalra PA
Nephrology (Carlton); 2016 Jul; 21(7):566-73. PubMed ID: 27334353
[TBL] [Abstract][Full Text] [Related]
26. FGF23 and Klotho in chronic kidney disease.
Olauson H; Larsson TE
Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):397-404. PubMed ID: 23666415
[TBL] [Abstract][Full Text] [Related]
27. [FGF23 and the heart].
Ezumba I; Quarles LD; Kovesdy CP
G Ital Nefrol; 2014; 31(6):. PubMed ID: 25504170
[TBL] [Abstract][Full Text] [Related]
28. Strength of Fibroblast Growth Factor 23 as a Cardiovascular Risk Predictor in Chronic Kidney Disease Weaken by ProBNP Adjustment.
Emrich IE; Brandenburg V; Sellier AB; Schauerte J; Wiedenroth J; Untersteller K; Lennartz CS; Seiler-Mussler S; Wagenpfeil S; Fliser D; Heine GH
Am J Nephrol; 2019; 49(3):203-211. PubMed ID: 30808827
[TBL] [Abstract][Full Text] [Related]
29. Fibroblast growth factor 23 (FGF23) and mortality: the Ludwigshafen Risk and Cardiovascular Health Study.
Brandenburg VM; Kleber ME; Vervloet MG; Tomaschitz A; Pilz S; Stojakovic T; Delgado G; Grammer TB; Marx N; März W; Scharnagl H
Atherosclerosis; 2014 Nov; 237(1):53-9. PubMed ID: 25200615
[TBL] [Abstract][Full Text] [Related]
30. Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients.
Bech AP; Bouma-de Krijger A; van Zuilen AD; Bots ML; van den Brand JA; Blankestijn PJ; Wetzels JF; Vervloet MG
J Nephrol; 2015 Aug; 28(4):477-84. PubMed ID: 25700931
[TBL] [Abstract][Full Text] [Related]
31. FGF23 from bench to bedside.
Kovesdy CP; Quarles LD
Am J Physiol Renal Physiol; 2016 Jun; 310(11):F1168-74. PubMed ID: 26864938
[TBL] [Abstract][Full Text] [Related]
32. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease.
Leifheit-Nestler M; Große Siemer R; Flasbart K; Richter B; Kirchhoff F; Ziegler WH; Klintschar M; Becker JU; Erbersdobler A; Aufricht C; Seeman T; Fischer DC; Faul C; Haffner D
Nephrol Dial Transplant; 2016 Jul; 31(7):1088-99. PubMed ID: 26681731
[TBL] [Abstract][Full Text] [Related]
33. Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients.
Hsu HJ; Wu MS
Am J Med Sci; 2009 Feb; 337(2):116-22. PubMed ID: 19214027
[TBL] [Abstract][Full Text] [Related]
34. Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease.
Quarles LD
Exp Cell Res; 2012 May; 318(9):1040-8. PubMed ID: 22421513
[TBL] [Abstract][Full Text] [Related]
35. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active.
Shimada T; Urakawa I; Isakova T; Yamazaki Y; Epstein M; Wesseling-Perry K; Wolf M; Salusky IB; Jüppner H
J Clin Endocrinol Metab; 2010 Feb; 95(2):578-85. PubMed ID: 19965919
[TBL] [Abstract][Full Text] [Related]
36. Fibroblast Growth Factor 23 Predicts All-Cause Mortality in a Dose-Response Fashion in Pre-Dialysis Patients with Chronic Kidney Disease.
Xue C; Yang B; Zhou C; Dai B; Liu Y; Mao Z; Yu S; Mei C
Am J Nephrol; 2017; 45(2):149-159. PubMed ID: 28006765
[TBL] [Abstract][Full Text] [Related]
37. Time-averaged level of fibroblast growth factor-23 and clinical events in chronic kidney disease.
Bouma-de Krijger A; Bots ML; Vervloet MG; Blankestijn PJ; Ter Wee PW; van Zuilen AD; Wetzels JF
Nephrol Dial Transplant; 2014 Jan; 29(1):88-97. PubMed ID: 24215017
[TBL] [Abstract][Full Text] [Related]
38. FGF23 in chronic kidney disease.
Wahl P; Wolf M
Adv Exp Med Biol; 2012; 728():107-25. PubMed ID: 22396166
[TBL] [Abstract][Full Text] [Related]
39. Recent advances in the rapidly evolving field of fibroblast growth factor 23 in chronic kidney disease.
Zisman AL; Wolf M
Curr Opin Nephrol Hypertens; 2010 Jul; 19(4):335-42. PubMed ID: 20583336
[TBL] [Abstract][Full Text] [Related]
40. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment.
Seiler S; Reichart B; Roth D; Seibert E; Fliser D; Heine GH
Nephrol Dial Transplant; 2010 Dec; 25(12):3983-9. PubMed ID: 20525642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
